Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 9/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571639 | 0.87 | CXCR2 (0.49) | CXCR2GRIK1MEN1KMT2APOLB | |
| SCHEMBL7595003 | 0.85 | CXCR2 (0.52) | CXCR2GRIK1MEN1KMT2APOLB | |
| SCHEMBL3206570 | 0.83 | GRIK1 (0.49) | CXCR2GRIK1MEN1KMT2AFABP4 | |
| SCHEMBL11542345 | 0.79 | CXCR2 (0.53) | CXCR2MEN1KMT2AMAPK8FABP4 | |
| SCHEMBL7577106 | 0.74 | CXCR2 (0.52) | CXCR2MEN1KMT2APOLBMAPT | |
| SCHEMBL7573159 | 0.74 | CXCR2 (0.47) | CXCR2GRIK1MEN1KMT2ATAS2R14 | |
| SCHEMBL7572551 | 0.71 | CXCR2 (0.63) | CXCR2GRIK1MAPK8FABP4TAS2R14 | |
| SCHEMBL7662910 | 0.70 | TAS2R14 (0.56) | CXCR2MEN1KMT2AFABP4TAS2R14 | |
| SCHEMBL16621392 | 0.68 | AKR1C3 (0.53) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL1686500 | 0.68 | MEN1 (0.55) | MEN1KMT2AMAPTPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117633-B1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2002-09-18 | — | — | EP | disclosed |
| US-6413996-B2 | CHLORIDE CHANNEL BLOCKERS; FOR TREATMENT OF SICKLE CELL ANAEMIA, BRAIN OEDEMA FOLLOWING ISCHAEMIA OR TUMOURS, DIARRHOEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, BONE METASTASIZING CANCERS | NEUROSEARCH A/S (DK) | 2002-07-02 | — | — | US | disclosed |
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | ANIONA APS (DK) | 2001-12-27 | — | — | US | disclosed |
| EP-1117633-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020378-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | HCN4, CLIC1, KCNB1 | CXCR2 415/4885GRIK1 1228/4885MEN1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.